Novel pharmacologic targeting of tight junctions and focal adhesions in prostate cancer cells

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Cancer cells resist anoikis, leading to invasion and therapeutic resistance.
• The tumor microenvironment sustains aberrant signaling pathways.
• Advanced prostate cancer poses significant therapeutic challenges.

Purpose of the Study:

• To investigate the novel quinazoline-based Doxazosin derivative, DZ-50, as a potential therapeutic agent for advanced prostate cancer.
• To elucidate the molecular mechanisms by which DZ-50 inhibits tumor growth and metastasis.
• To identify the key cellular interactions targeted by DZ-50.

Main Methods:

• Genome-wide analysis of human prostate cancer cell line DU-145 to identify DZ-50 downregulated targets.
• Confocal microscopy to assess structural disruption of focal adhesions and tight junctions.
• Manipulation of gene expression (talin-1) and extracellular matrix components (fibronectin) to evaluate DZ-50 effects.

Main Results:

• DZ-50 downregulated key genes in focal adhesion (fibronectin, integrin-α6, talin) and tight junction (claudin-11) integrity.
• DZ-50 caused structural disruption of focal adhesions and tight junctions, decreasing cancer cell survival, migration, and adhesion.
• Overexpression of talin-1 or fibronectin-rich environments mitigated DZ-50's effects.
• Loss of talin-1 and integrin linked kinase (ILK) sensitized prostate cancer cells to anoikis.

Conclusions:

• DZ-50 exerts antitumor effects by targeting critical intercellular interactions, specifically focal adhesions and tight junctions.
• The disruption of these interactions leads to anoikis, inhibiting cancer cell survival and metastasis.
• DZ-50 demonstrates significant therapeutic potential for advanced prostate cancer treatment.